Summary of Results:
- A single injection of NMN reduces blood lipid levels by approximately 75%.
- NMN injections are safely metabolized and do not cause any observable damage to the heart, kidneys, or pancreas, despite bypassing the body's detoxification organ - the liver.
- The injections increase blood levels of NAD+ by approximately 20%.
Summary of the Study:
Increasing levels of nicotinamide adenine dinucleotide (NAD+) alleviate the progression of age-related diseases and promote healthy lifespan. Several studies have demonstrated that NAD+ levels can be efficiently replenished by taking nicotinamide mononucleotide (NMN). Moreover, the safety of oral intake has been confirmed in recent clinical trials. However, the efficacy and safety of intravenous NMN administration in humans remain unclear. Therefore, we assessed its safety in 10 healthy volunteers. Intravenous NMN administration had no effect on electrocardiograms, pulse, and blood pressure, and also did not negatively impact metabolic markers in the liver, heart, pancreas, and kidneys. These results indicate that intravenous NMN administration is safe and beneficial in humans. Furthermore, NMN administration significantly increased blood levels of NAD+ without causing harm to blood cells, and it significantly decreased blood triglyceride (TG) levels. These findings suggest that intravenous NMN administration may lead to the prevention and treatment of diseases associated with elevated TG levels, such as fatty liver and diabetes.
Source: https://pubmed.ncbi.nlm.nih.gov/36002548/
